Aclaris Therapeutics

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Aclaris Therapeutics reports Q1 earnings, highlights ATI-450 trial results

Aclaris Therapeutics reported financial highlights, discussed trial results for ATI-450, and highlighted optimism about its pipeline.
Strengths include targeted PD inhibition in HS study, competitive landscape discussions in atopic dermatitis, and changes in inclusion criteria for studies.
Challenges involve CNS adverse events in HS study, enrollment hurdles in psoriatic arthritis trial, and scrutiny on CK elevations and comparisons to other therapies.
Opportunities lie in potential value creation in immune-inflammatory diseases, market positioning in atopic dermatitis, and patient engagement strategies in RA and PSA studies.

Aclaris Therapeutics progresses ATI-2138 for atopic dermatitis, eyes growth

Aclaris Therapeutics is focused on advancing ATI-2138 for atopic dermatitis with a strong financial position. While facing questions on various fronts, the company's strategic direction and commitment to innovation offer promising opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow